Mechanism of action of bile-gut axis in the development and progression of intrahepatic cholangiocarcinoma

Xue YU; Tianhao SHEN; Cheng ZHOU; Yu LIU; Wei LI; Tinghui JIANG; Yongqiang ZHU; Yan LIU

doi:10.12449/JCH250330

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 588-593

PDF( 1044 KB)

Mechanism of action of bile-gut axis in the development and progression of intrahepatic cholangiocarcinoma

DOI: 10.12449/JCH250330

1.
Department of Interventional Oncology, Putuo Hospital Shanghai University of Traditional Chinese Medicine，Shanghai 200062，China
2.
Department of Hepatobiliary Minimally Invasive Surgery, Putuo Hospital Shanghai University of Traditional Chinese Medicine，Shanghai 200062，China

Research funding:

Talent Program of Shanghai Municipal Health Commission (2022YQ037);

Shanghai Putuo District Health System Science and Technology Innovation Project Plan (ptkwws202210);

Shanghai Putuo Central Hospital Clinical Talent Program (2022-RCJC-07)

More Information

Corresponding author: LIU Yan， liuyan3491542@shutcm.edu.cn （ORCID： 0000-0001-7205-1569）
Received Date: 2024-08-01
Accepted Date: 2024-09-23
Published Date: 2025-03-25

Abstract

Abstract

Intrahepatic cholangiocarcinoma is a malignant tumor with an extremely poor prognosis， and its pathogenesis is complex and remains unclear. In recent years， more and more studies have focused on the role of bile-gut axis in the development and progression of intrahepatic cholangiocarcinoma. Bile-gut axis refers to the complex interaction between bile and gut microbiota， including bile salt metabolism， dynamic changes of microbiota， inflammatory response， and immune system regulation. This article elaborates on the potential mechanisms of bile-gut axis in intrahepatic cholangiocarcinoma， especially gut microbiota dysbiosis， abnormal bile salt metabolism， chronic inflammatory response， and immune system interaction， this article aims to provide new perspectives and possible therapeutic targets for future research and promote the early diagnosis and effective treatment of intrahepatic cholangiocarcinoma.
- Cholangiocarcinoma,
- Bile-Gut Axis,
- Gastrointestinal Microbiome,
- Bile Salt Metabolism,
- Inflammation

FullText(HTML)

References(55)

References

[1]	FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144( 8): 1941- 1953. DOI: 10.1002/ijc.31937.
[2]	AN L, ZHENG RS, ZHANG SW, et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: Estimates based on data from 188 population-based cancer registries[J]. Hepatobiliary Surg Nutr, 2023, 12( 1): 45- 55. DOI: 10.21037/hbsn-21-75.
[3]	SIEGEL RL, MILLER KD, WAGLE NS, et al. Cancer statistics, 2023[J]. CA A Cancer J Clin, 2023, 73( 1): 17- 48. DOI: 10.3322/caac.21763.
[4]	WEI WQ, ZENG HM, ZHENG RS, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020, 21( 7): e342- e349. DOI: 10.1016/S1470-2045(20)30073-5.
[5]	KHAN AS, DAGEFORDE LA. Cholangiocarcinoma[J]. Surg Clin North Am, 2019, 99( 2): 315- 335. DOI: 10.1016/j.suc.2018.12.004.
[6]	KNITTER S, RASCHZOK N, HILLEBRANDT KH, et al. Short-term postoperative outcomes of lymphadenectomy for cholangiocarcinoma, hepatocellular carcinoma and colorectal liver metastases in the modern era of liver surgery: Insights from the StuDoQ\|Liver registry[J]. Eur J Surg Oncol, 2024, 50( 4): 108010. DOI: 10.1016/j.ejso.2024.108010.
[7]	LI ML, LIU FT, ZHANG F, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis[J]. Gut, 2019, 68( 6): 1024- 1033. DOI: 10.1136/gutjnl-2018-316039.
[8]	SAHU S, SUN WJ. Targeted therapy in biliary tract cancers-current limitations and potentials in the future[J]. J Gastrointest Oncol, 2017, 8( 2): 324- 336. DOI: 10.21037/jgo.2016.09.16.
[9]	TOLEDO B, DEIANA C, SCIANÒ F, et al. Treatment resistance in pancreatic and biliary tract cancer: Molecular and clinical pharmacology perspectives[J]. Expert Rev Clin Pharmacol, 2024, 17( 4): 323- 347. DOI: 10.1080/17512433.2024.2319340.
[10]	COSGROVE DP, REESE ES, FULCHER NM, et al. Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment[J]. Cancer Med, 2023, 12( 4): 4195- 4205. DOI: 10.1002/cam4.5282.
[11]	SATO K, HAYASHI M, ABE K, et al. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: A case report[J]. Clin J Gastroenterol, 2020, 13( 6): 1310- 1314. DOI: 10.1007/s12328-020-01178-5.
[12]	MAWSON AR, CROFT AM, GONZALEZ-FERNANDEZ F. Liver damage and exposure to toxic concentrations of endogenous retinoids in the pathogenesis of COVID-19 disease: Hypothesis[J]. Viral Immunol, 2021, 34( 6): 376- 379. DOI: 10.1089/vim.2020.0330.
[13]	HU YF, LI SX, LIU HL, et al. Precirrhotic primary biliary cholangitis with portal hypertension: Bile duct injury correlate[J]. Gut Liver, 2024, 18( 5): 867- 876. DOI: 10.5009/gnl230468.
[14]	XIE LJ, RUAN DD, ZHANG JH, et al. Mutational analysis of a familial adenomatous polyposis pedigree with bile duct polyp phenotype[J]. Can J Gastroenterol Hepatol, 2021, 2021: 6610434. DOI: 10.1155/2021/6610434.
[15]	OVERI D, CARPINO G, CRISTOFERI L, et al. Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis[J]. JHEP Rep, 2022, 4( 11): 100556. DOI: 10.1016/j.jhepr.2022.100556.
[16]	LIN CA, WANG YW, LIU CY, et al. Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis[J]. Clin Exp Immunol, 2024, 215( 3): 225- 239. DOI: 10.1093/cei/uxad117.
[17]	ARREAZA-GIL V, ESCOBAR-MARTÍNEZ I, MUGUERZA B, et al. The effects of grape seed proanthocyanidins in Cafeteria diet-induced obese Fischer 344 rats are influenced by faecal microbiota in a photoperiod dependent manner[J]. Food Funct, 2022, 13( 16): 8363- 8374. DOI: 10.1039/d2fo01206e.
[18]	FARSHBAFNADI M, AGAH E, REZAEI N. The second brain: The connection between gut microbiota composition and multiple sclerosis[J]. J Neuroimmunol, 2021, 360: 577700. DOI: 10.1016/j.jneuroim.2021.577700.
[19]	SOTTAS C, SCHMIEDOVÁ L, KREISINGER J, et al. Gut microbiota in two recently diverged passerine species: Evaluating the effects of species identity, habitat use and geographic distance[J]. BMC Ecol Evol, 2021, 21( 1): 41. DOI: 10.1186/s12862-021-01773-1.
[20]	GU SM, XIE Q, CHEN C, et al. Gut microbial signatures associated with peanut allergy in a BALB/c mouse model[J]. Foods, 2022, 11( 10): 1395. DOI: 10.3390/foods11101395.
[21]	KIM JK, CHOI MS, KIM JY, et al. Ginkgo biloba leaf extract suppresses intestinal human breast cancer resistance protein expression in mice: Correlation with gut microbiota[J]. Biomed Pharmacother, 2021, 140: 111712. DOI: 10.1016/j.biopha.2021.111712.
[22]	VERHAAR BJH, MOSTERD CM, COLLARD D, et al. Sex differences in associations of plasma metabolites with blood pressure and heart rate variability: The HELIUS study[J]. Atherosclerosis, 2023, 384: 117147. DOI: 10.1016/j.atherosclerosis.2023.05.016.
[23]	MIHAJLOVIC J, LEUTNER M, HAUSMANN B, et al. Combined hormonal contraceptives are associated with minor changes in composition and diversity in gut microbiota of healthy women[J]. Environ Microbiol, 2021, 23( 6): 3037- 3047. DOI: 10.1111/1462-2920.15517.
[24]	SAAB M, MESTIVIER D, SOHRABI M, et al. Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma[J]. PLoS One, 2021, 16( 3): e0247798. DOI: 10.1371/journal.pone.0247798.
[25]	LIU XJ, CHENG Y, ZANG D, et al. The role of gut microbiota in lung cancer: From carcinogenesis to immunotherapy[J]. Front Oncol, 2021, 11: 720842. DOI: 10.3389/fonc.2021.720842.
[26]	LI T, WANG PL, YUAN ZB, et al. Changes in intestinal flora in patients with extrahepatic cholangiocarcinoma[J]. J Clin Hepatol, 2021, 37( 12): 2883- 2889. DOI: 10.3969/j.issn.1001-5256.2021.12.029. 李涛, 王盼梁, 袁梓博, 等. 肝外肝内胆管癌患者肠道菌群变化分析[J]. 临床肝胆病杂志, 2021, 37( 12): 2883- 2889. DOI: 10.3969/j.issn.1001-5256.2021.12.029.
[27]	HUANG H, ZHONG W, WANG XJ, et al. The role of gastric microecological dysbiosis in gastric carcinogenesis[J]. Front Microbiol, 2023, 14: 1218395. DOI: 10.3389/fmicb.2023.1218395.
[28]	MADSEN C. The role of oral health in gastrointestinal malignancies[J]. J Gastrointest Oncol, 2021, 12( Suppl 2): S311- S315. DOI: 10.21037/jgo.2020.02.03.
[29]	LIU TY, GUO ZX, SONG XL, et al. High-fat diet-induced dysbiosis mediates MCP-1/CCR2 axis-dependent M2 macrophage polarization and promotes intestinal adenoma-adenocarcinoma sequence[J]. J Cell Mol Med, 2020, 24( 4): 2648- 2662. DOI: 10.1111/jcmm.14984.
[30]	FAN XY, JIN YL, CHEN G, et al. Gut microbiota dysbiosis drives the development of colorectal cancer[J]. Digestion, 2021, 102( 4): 508- 515. DOI: 10.1159/000508328.
[31]	CUI H, LIAN J, XU BG, et al. Identification of a bile acid and bile salt metabolism-related lncRNA signature for predicting prognosis and treatment response in hepatocellular carcinoma[J]. Sci Rep, 2023, 13( 1): 19512. DOI: 10.1038/s41598-023-46805-6.
[32]	CAMILLERI M. Bile acid detergency: Permeability, inflammation, and effects of sulfation[J]. Am J Physiol Gastrointest Liver Physiol, 2022, 322( 5): G480- G488. DOI: 10.1152/ajpgi.00011.2022.
[33]	WANG N, YU XH, XU L. Intestinal flora and cholangiocarcinoma: Research progress[J]. Chin J Microecol, 2018, 30( 11): 1339- 1342. DOI: 10.13381/j.cnki.cjm.201811024. 王宁, 于兴华, 许琳. 肠道菌群的研究进展及与肝内胆管癌的关系分析[J]. 中国微生态学杂志, 2018, 30( 11): 1339- 1342. DOI: 10.13381/j.cnki.cjm.201811024.
[34]	BRUNEAU A, HUNDERTMARK J, GUILLOT A, et al. Molecular and cellular mediators of the gut-liver axis in the progression of liver diseases[J]. Front Med(Lausanne), 2021, 8: 725390. DOI: 10.3389/fmed.2021.725390.
[35]	WANG DH, ZHANG XS, DU HW. Inflammatory bowel disease: A potential pathogenic factor of Alzheimer’s disease[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2022, 119: 110610. DOI: 10.1016/j.pnpbp.2022.110610.
[36]	ZOU ZJ, LIN HF, LI MS, et al. Tumor-associated macrophage polarization in the inflammatory tumor microenvironment[J]. Front Oncol, 2023, 13: 1103149. DOI: 10.3389/fonc.2023.1103149.
[37]	LI LH, YU R, CAI TG, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment[J]. Int Immunopharmacol, 2020, 88: 106939. DOI: 10.1016/j.intimp.2020.106939.
[38]	SAHOO DK, BORCHERDING DC, CHANDRA L, et al. Differential transcriptomic profiles following stimulation with lipopolysaccharide in intestinal organoids from dogs with inflammatory bowel disease and intestinal mast cell tumor[J]. Cancers(Basel), 2022, 14( 14): 3525. DOI: 10.3390/cancers14143525.
[39]	VIGNJEVIĆ PETRINOVIĆ S, MILOŠEVIĆ MS, MARKOVIĆ D, et al. Interplay between stress and cancer-a focus on inflammation[J]. Front Physiol, 2023, 14: 1119095. DOI: 10.3389/fphys.2023.1119095.
[40]	AL-RAJABI R, SUN WJ. Immunotherapy in cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2021, 37( 2): 105- 111. DOI: 10.1097/MOG.0000000000000715.
[41]	WITSCHEN PM, CHAFFEE TS, BRADY NJ, et al. Tumor cell associated hyaluronan-CD44 signaling promotes pro-tumor inflammation in breast cancer[J]. Cancers(Basel), 2020, 12( 5): 1325. DOI: 10.3390/cancers12051325.
[42]	TAN ZF, XUE HB, SUN YL, et al. The role of tumor inflammatory microenvironment in lung cancer[J]. Front Pharmacol, 2021, 12: 688625. DOI: 10.3389/fphar.2021.688625.
[43]	LIU GL, DOU J, MENG HJ, et al. Value of immune-inflammatory factors in predicting intrahepatic cholangiocarcinoma[J]. J Clin Hepatol, 2023, 39( 9): 2231- 2236. DOI: 10.3969/j.issn.1001-5256.2023.09.030. 刘桂玲, 窦杰, 孟慧娟, 等. 免疫炎症因子在肝内肝内胆管癌中的预测价值[J]. 临床肝胆病杂志, 2023, 39( 9): 2231- 2236. DOI: 10.3969/j.issn.1001-5256.2023.09.030.
[44]	SCIMECA M, ROVELLA V, PALUMBO V, et al. Programmed cell death pathways in cholangiocarcinoma: Opportunities for targeted therapy[J]. Cancers(Basel), 2023, 15( 14): 3638. DOI: 10.3390/cancers15143638.
[45]	CHEN S, WANG J. Advances in tumor microenvironment and immunotherapy of Cholangiocarcinoma[J]. J Clin Hepatol, 2022, 38( 10): 2428- 2432. DOI: 10.3969/j.issn.1001-5256.2022.10.044. 陈顺, 王俊. 肝内胆管癌肿瘤微环境与免疫治疗[J]. 临床肝胆病杂志, 2022, 38( 10): 2428- 2432. DOI: 10.3969/j.issn.1001-5256.2022.10.044.
[46]	XIA T, LI KY, NIU N, et al. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses[J]. J Hematol Oncol, 2022, 15( 1): 37. DOI: 10.1186/s13045-022-01253-z.
[47]	ALVISI G, TERMANINI A, SOLDANI C, et al. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target[J]. J Hepatol, 2022, 77( 5): 1359- 1372. DOI: 10.1016/j.jhep.2022.05.043.
[48]	ZHANG ZJ, HUANG YP, LIU ZT, et al. Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients[J]. Front Immunol, 2023, 14: 1028404. DOI: 10.3389/fimmu.2023.1028404.
[49]	ZHOU GY, LIESHOUT R, van TIENDEREN GS, et al. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells[J]. Br J Cancer, 2022, 127( 4): 649- 660. DOI: 10.1038/s41416-022-01839-x.
[50]	GRETEN TF, SCHWABE R, BARDEESY N, et al. Immunology and immunotherapy of cholangiocarcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 6): 349- 365. DOI: 10.1038/s41575-022-00741-4.
[51]	CAZZETTA V, FRANZESE S, CARENZA C, et al. Natural killer-dendritic cell interactions in liver cancer: Implications for immunotherapy[J]. Cancers(Basel), 2021, 13( 9): 2184. DOI: 10.3390/cancers13092184.
[52]	CHEN ZM, CHEN JH. Advances in precision diagnosis and treatment of cholangiocarcinoma[J]. Chin J Clin Pharmacol Ther, 2025, 30( 2): 159- 170. DOI: 10.12092/j.issn.1009-2501.2025.02.002. 陈祯美, 陈进宏. 肝内胆管癌精准诊疗进展及前沿[J]. 中国临床药理学与治疗学, 2025, 30( 2): 159- 170. DOI: 10.12092/j.issn.1009-2501.2025.02.002.
[53]	YU XZ, ZHU LL, WANG T, et al. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies[J]. Front Immunol, 2023, 14: 1037945. DOI: 10.3389/fimmu.2023.1037945.
[54]	CHIANG NJ, HOU YC, TAN KT, et al. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma[J]. Hepatol Int, 2022, 16( 5): 1137- 1149. DOI: 10.1007/s12072-022-10346-3.
[55]	KIDA A, MIZUKOSHI E, KITAHARA M, et al. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma[J]. Int J Cancer, 2024, 154( 4): 738- 747. DOI: 10.1002/ijc.34716.

Relative Articles

[1]	Ke SHI, Qun ZHANG, Xianbo WANG, Ying FENG. Effect of intestinal flora and metabolites on the development and progression of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2025, 41(3): 568-573. doi: 10.12449/JCH250327
[2]	Yunchong WU, Yanyan YANG, Chuan LI, Xiaohuan WU, Shide LIN. Role of inflammatory cytokines in disorder of glucose metabolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1886-1890. doi: 10.12449/JCH240926
[3]	Yuyan XIA, Qiongrong ZENG, Fujian LI, Fengyan LI, Qi LI, Lixia TANG, Guo ZHANG. Association of intestinal microecology with the development and progression of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(2): 374-379. doi: 10.12449/JCH240225
[4]	Guiling LIU, Jie DOU, Huijuan MENG, Bingqi MA. Value of immune－inflammatory factors in predicting intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(9): 2231-2236. doi: 10.3969/j.issn.1001-5256.2023.09.030
[5]	Minghan MA, Yanqi LIU. Treatment of primary biliary cholangitis by targeting intestinal flora[J]. Journal of Clinical Hepatology, 2023, 39(1): 188-191. doi: 10.3969/j.issn.1001-5256.2023.01.029
[6]	Yongqiang LI, Wenjuan TANG, Yongjian ZHOU. Role of intestinal microbiota and metabolites in the development, progression, and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(8): 1805-1810. doi: 10.3969/j.issn.1001-5256.2023.08.006
[7]	Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
[8]	Yanying GAO, Huiling XIANG, Jing LIANG, Tao HAN, Xu ZHANG. Mechanism of intestinal flora imbalance in the development and progression of liver cancer and the role of probiotics in preventing liver cancer[J]. Journal of Clinical Hepatology, 2022, 38(3): 699-702. doi: 10.3969/j.issn.1001-5256.2022.03.042
[9]	Qingling ZHONG, Liangping LI. Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(6): 1411-1415. doi: 10.3969/j.issn.1001-5256.2022.06.040
[10]	Handong ZHAO, Peng GAO, Li ZHAN. The mechanism of intestinal flora and its metabolites in the formation of cholesterol gallstones[J]. Journal of Clinical Hepatology, 2022, 38(4): 947-950. doi: 10.3969/j.issn.1001-5256.2022.04.042
[11]	Shenglan ZENG, Rongzhen ZHANG, Na WANG, Tingshuai WANG, Liting TAN, Dewen MAO. Effect of diet-gut microbiota axis on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2676-2679. doi: 10.3969/j.issn.1001-5256.2021.11.041
[12]	Yu LIU, Yuyi ZHANG, Ying ZOU, Wei YUAN, Hongying GUO, Xue MEI, Jiefei WANG, Zhiping QIAN. Association between intestinal microecology and spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2021, 37(2): 425-428. doi: 10.3969/j.issn.1001-5256.2021.02.037
[13]	Yanyan CHEN, Yanmei LAN, Minggang WANG, Dewen. MAO. Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration[J]. Journal of Clinical Hepatology, 2021, 37(2): 480-484. doi: 10.3969/j.issn.1001-5256.2021.02.049
[14]	Yangyang XIONG, Dong WU, Jiaming QIAN. Role of gut microbiota and its metabolites in severe acute pancreatitis-related acute respiratory distress syndrome[J]. Journal of Clinical Hepatology, 2021, 37(1): 233-236. doi: 10.3969/j.issn.1001-5256.2021.01.052
[15]	Lidan YANG, He HE, Zhenmei AN. Role of intestinal flora in metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2231-2235. doi: 10.3969/j.issn.1001-5256.2021.09.046
[16]	Tao LI, Panliang WANG, Zibo YUAN, Quankai FENG, Jie LI. Changes in intestinal flora in patients with extrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2883-2889. doi: 10.3969/j.issn.1001-5256.2021.12.029
[17]	Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
[18]	Li KeZhi, Wei JiaKang, Han ZhiWei, Chou WenXia, Chen XinXin, Huang Shan, He JianBo, Wu GuoBin, Chen Chuang. Changes in intestinal flora in patients with primary liver cancer after transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(5): 1043-1049. doi: 10.3969/j.issn.1001-5256.2020.05.019
[19]	Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
[20]	Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (48) PDF downloads(7)

Mechanism of action of bile-gut axis in the development and progression of intrahepatic cholangiocarcinoma

DOI: 10.12449/JCH250330

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of action of bile-gut axis in the development and progression of intrahepatic cholangiocarcinoma

DOI: 10.12449/JCH250330

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content